BRUERA, GEMMA
 Distribuzione geografica
Continente #
NA - Nord America 841
EU - Europa 621
AS - Asia 413
SA - Sud America 82
Totale 1.957
Nazione #
US - Stati Uniti d'America 832
IE - Irlanda 188
SG - Singapore 172
CN - Cina 115
DE - Germania 76
BR - Brasile 73
IT - Italia 71
RU - Federazione Russa 67
SE - Svezia 62
TR - Turchia 59
HK - Hong Kong 41
UA - Ucraina 38
FI - Finlandia 31
FR - Francia 26
GB - Regno Unito 26
CZ - Repubblica Ceca 21
VN - Vietnam 10
IQ - Iraq 4
CA - Canada 3
DM - Dominica 3
IN - India 3
MX - Messico 3
PT - Portogallo 3
AR - Argentina 2
BD - Bangladesh 2
BE - Belgio 2
BN - Brunei Darussalam 2
CL - Cile 2
ES - Italia 2
NL - Olanda 2
PY - Paraguay 2
AT - Austria 1
BY - Bielorussia 1
EC - Ecuador 1
HU - Ungheria 1
JO - Giordania 1
MD - Moldavia 1
PE - Perù 1
PK - Pakistan 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SY - Repubblica araba siriana 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 1.957
Città #
Chandler 216
Dublin 188
Jacksonville 159
Singapore 86
Boardman 53
Santa Clara 50
Hong Kong 40
Ashburn 28
New York 27
Izmir 26
Nanjing 26
Beijing 25
Bremen 25
Lawrence 25
Princeton 25
Wilmington 22
Brno 21
Helsinki 19
Moscow 14
Nanchang 11
San Mateo 11
Dong Ket 10
Pescara 10
Ann Arbor 8
L’Aquila 8
Munich 8
São Paulo 8
Falkenstein 7
Hebei 7
Milan 7
Woodbridge 7
Council Bluffs 5
Kunming 5
Rome 5
Tianjin 5
Changsha 4
San Francisco 4
Seattle 4
Dearborn 3
Des Moines 3
Jiaxing 3
L'aquila 3
Mountain View 3
Redwood City 3
Roseau 3
Shenyang 3
Washington 3
Baghdad 2
Bandar Seri Begawan 2
Betim 2
Borås 2
Brussels 2
Campinas 2
Duhok 2
Gramado 2
Guangzhou 2
Jinan 2
Lisburn 2
Monza 2
Norwalk 2
Philadelphia 2
Shanghai 2
Taubaté 2
Toronto 2
Trestina 2
Alvorada 1
Amman 1
Apodaca 1
Baotou 1
Barbacena 1
Bauru 1
Belo Horizonte 1
Belém 1
Berlin 1
Boretto 1
Botucatu 1
Bucharest 1
Budapest 1
Bursa 1
Campanha 1
Campo Grande 1
Carapicuíba 1
Caruaru 1
Changchun 1
Changzhou 1
Chapecó 1
Chisinau 1
Ciudad del Este 1
Confresa 1
Curitiba 1
Dallas 1
Delhi 1
Dhaka 1
Duque de Caxias 1
Espoo 1
Formosa 1
Frankfurt am Main 1
Fremont 1
Fuzhou 1
Guaratuba 1
Totale 1.307
Nome #
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 148
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 119
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 110
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 104
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 99
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 97
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 90
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 88
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 83
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 82
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 77
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 77
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 76
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 76
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 74
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 74
Stravaso da antracicline: il punto di vista dell’oncologo. Caso clinico. 69
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 66
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 64
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 63
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 63
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice 61
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments 57
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease 56
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice 54
PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice 17
Totale 2.044
Categoria #
all - tutte 9.395
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.395


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 0 0 0 0 20
2020/2021197 1 21 4 21 33 8 27 4 26 6 30 16
2021/2022130 5 3 31 7 5 0 0 7 10 0 9 53
2022/2023579 27 42 2 79 55 67 2 32 244 0 12 17
2023/2024135 19 9 9 12 8 38 8 4 0 2 3 23
2024/2025558 35 12 43 38 86 46 99 53 131 15 0 0
Totale 2.044